Clinical trial
A Phase 2, Randomized, Double Blind, Placebo Controlled Study of the Safety, PK, and PD of Multiple Doses of ISIS 416858 (ISIS-FXI RX), Administered Subcutaneously to Patients With End-Stage Renal Disease on Hemodialysis
NCT02553889 is registered in ClinicalTrials.gov with Ionis Pharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomized, Double Blind, Placebo Controlled Study of the Safety, PK, and PD of Multiple Doses of ISIS 416858 (ISIS-FXI RX), Administered Subcutaneously to Patients With End-Stage Renal Disease on Hemodialysis
- Lead sponsor
- Ionis Pharmaceuticals, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- October 31, 2015
- Completion date
- November 30, 2016
- Enrollment
- 49 (actual)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.
end-stage renal disease (esrd)